Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Fibrogen Inc patents (2015 archive)


Recent patent applications related to Fibrogen Inc. Fibrogen Inc is listed as an Agent/Assignee. Note: Fibrogen Inc may have other listings under different names/spellings. We're not affiliated with Fibrogen Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "F" | Fibrogen Inc-related inventors


12/31/15 / #20150376270

Treatment method for lung remodeling diseases

The present invention relates to methods and medicaments useful for pre-treatment, treatment, or amelioration of lung remodeling disease. Methods and medicaments for reducing, preventing, or reversing increased lung density, improving lung function, and increasing survivability in subjects having lung remodeling disease are also provided.. ... Fibrogen Inc

11/12/15 / #20150322015

Crystalline forms of a prolyl hydroxylase inhibitor

The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. . ... Fibrogen Inc

07/30/15 / #20150210760

Therapeutic method for pancreatic cancer

The present invention relates to methods and medicarnents useful for treating locally advanced pancreatic cancer (lapc). Improved therapeutic methods and regimens comprising anti-connective tissue growth factor (ctgf) agents, including anti-ctgf antibodies, are provided. ... Fibrogen Inc

07/30/15 / #20150209336

Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity

The present invention relates to novel compounds according to formula i or ii, methods, and compositions capable of decreasing hif hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (hif). Formula (i) or (ii).. ... Fibrogen Inc

07/02/15 / #20150182528

Thiochromene derivatives as hif hydroxylase inhibitors

The present invention relates to novel compounds, methods, and compositions capable of decreasing hif hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (hif).. . ... Fibrogen Inc

06/25/15 / #20150175550

Process for making isoquinoline compounds

The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing hif hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (hif).. ... Fibrogen Inc

06/25/15 / #20150174110

Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase

The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting hif hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (hif).. . ... Fibrogen Inc

05/28/15 / #20150147340

Therapeutic methods for peritoneal carcinomatosis

Described herein are methods and medicaments useful for treating peritoneal carcinomatosis by administering anti-ctgf agents, particularly anti-ctgf antibodies. Methods for prognosing individuals with perinoteal carcinomatosis are also provided. ... Fibrogen Inc

05/07/15 / #20150126620

Methods for treating anemia

The present invention relates to improved methods and compounds for treating anemia. Screening methods to identify agents for use in these treatment methods are also provided.. ... Fibrogen Inc

03/26/15 / #20150086483

Methods for treating idiopathic pulmonary fibrosis

The present invention relates to methods and medicaments useful for treating idiopathic pulmonary fibrosis (iff) by administering anti-ctgf antibodies. Methods for prognosing individuals with ipf are also provided.. ... Fibrogen Inc

03/19/15 / #20150080425

Methods for treating anemia in subjects having kidney failure using inhibitors of hypoxia-inducible factor (hif) hydroxylase

The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (hif) prolyl hydroxylase.. . ... Fibrogen Inc

02/05/15 / #20150038529

Crystalline forms of a prolyl hydroxylase inhibitor

The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. . ... Fibrogen Inc

02/05/15 / #20150038528

4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors

The present invention relates to novel compounds of formula (i), and compositions capable of inhibiting phd1 enzyme activity selectively over other isoforms, for example, phd2 and/or phd3 enzymes. The invention also relates to compounds of formula (i) for use in disorders such as muscle degeneration, colitis, ibd, and certain ischemias.. ... Fibrogen Inc

01/29/15 / #20150031696

Cyanoisoquinoline compounds and methods of use thereof

The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:. ... Fibrogen Inc

01/15/15 / #20150018384

Treatment for high cholesterol

The present invention provides a method for treatment of high cholesterol by reducing low density lipoprotein cholesterol (ldl-c) and/or very low density opoproiein cholesterol (vldl-c) in subjects in need thereof by administering a compound that inhibits hif hydroxylase activity. The method is useful, for reducing ldl cholesterol levels and total cholesterol levels even in subjects already undergoing treatment with other cholesterol-lowering medications, for example statins, fibrates, nicotinic acids and bile acid-binding resins, and in patients having chronic kidney disease or end stage renal disease, inter alia.. ... Fibrogen Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Fibrogen Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Fibrogen Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###